NSCLC patients with wild-type EGFR were more likely to lose bodyweight than NSCLC patients with mutant EGFR (116/166 [69.9%] vs. 97/198 [49.0%], respectively, p < 0.0001). Here, EGFR is linked to non-small cell lung carcinoma.